Miguel Xavier
Fernandes
Researcher in the period 2013-2022
University of Belgrade
Belgrado, SerbiaPublications in collaboration with researchers from University of Belgrade (3)
2022
-
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors
Frontiers in Pharmacology, Vol. 13
2020
-
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells
Investigational New Drugs, Vol. 38, Núm. 3, pp. 584-598
2017
-
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells
European Journal of Pharmaceutical Sciences, Vol. 105, pp. 159-168